Biotech firms, particularly in Boston and Cambridge, hoped 2023 would mark a return to growth due to scientific innovations and economic conditions. However, the mood has shifted as the biotech index fell nearly 5% and significant layoffs persisted. Although there have been positive developments, the sector grapples with unprecedented unleased lab space and a prolonged four-year downturn. Experts like Alexis Borisy emphasize the need for stability to foster innovation in drug development, pointing to the volatility and uncertainty that continue to hamper progress.
The turbulent biotech landscape has left firms in a precarious position, with many limping along amid plunging valuations and uncertainty.
Despite some successes, the industry remains trapped in a four-year slump with hiring softening and biotech stocks down nearly five percent this year.
Collection
[
|
...
]